Gregory S. Emch

Array ( [id] => 17497840 [patent_doc_number] => 11286533 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-29 [patent_title] => Biomarkers of chronic lymphocytic leukemia and use thereof [patent_app_type] => utility [patent_app_number] => 16/063784 [patent_app_country] => US [patent_app_date] => 2016-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 13851 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16063784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17103122 [patent_doc_number] => 11123311 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-21 [patent_title] => Methods of treating mental disorders [patent_app_type] => utility [patent_app_number] => 16/065907 [patent_app_country] => US [patent_app_date] => 2016-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 26104 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13944711 [patent_doc_number] => 10208111 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-19 [patent_title] => Alpha-synuclein antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 15/355543 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 63 [patent_no_of_words] => 13224 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15355543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14497949 [patent_doc_number] => 20190192629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => Compositions Comprising CDNF or MANF for use in the Intranasal Treatment of Central Nervous System Diseases [patent_app_type] => utility [patent_app_number] => 15/777222 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5905 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15777222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11492632 [patent_doc_number] => 20170066817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-09 [patent_title] => 'MONOCLONAL ANTIBODY AGAINST HUMAN PRPC AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/351418 [patent_app_country] => US [patent_app_date] => 2016-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 6885 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15351418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11472801 [patent_doc_number] => 20170059585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'In vitro detection of prions in blood' [patent_app_type] => utility [patent_app_number] => 15/330832 [patent_app_country] => US [patent_app_date] => 2016-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 11590 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15330832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11441958 [patent_doc_number] => 20170042980 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'Degradation of Beta-Amyloid Proteins With Keratinase' [patent_app_type] => utility [patent_app_number] => 15/339093 [patent_app_country] => US [patent_app_date] => 2016-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 578 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15339093 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604085 [patent_doc_number] => 20170121385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'METHODS OF TREATING NEURODEGENERATIVE CONDITIONS' [patent_app_type] => utility [patent_app_number] => 15/338159 [patent_app_country] => US [patent_app_date] => 2016-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72492 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15338159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17268513 [patent_doc_number] => 11193933 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Measuring GAPDH protein for diagnosis and treatment of alzheimer's disease [patent_app_type] => utility [patent_app_number] => 15/335036 [patent_app_country] => US [patent_app_date] => 2016-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 3703 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15335036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12786412 [patent_doc_number] => 20180153973 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => DNA VACCINE AGAINST AMYLOID-BETA AND TAU [patent_app_type] => utility [patent_app_number] => 15/578123 [patent_app_country] => US [patent_app_date] => 2016-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14184 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15578123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11542650 [patent_doc_number] => 20170096476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'METHODS AND COMPOSITIONS RELATED TO AMYLOID-BETA-42 OLIGOMERS' [patent_app_type] => utility [patent_app_number] => 15/283779 [patent_app_country] => US [patent_app_date] => 2016-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 10162 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15283779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12368097 [patent_doc_number] => 09957568 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-01 [patent_title] => Administration of FGF9 for treatment and prevention of major depression [patent_app_type] => utility [patent_app_number] => 15/270193 [patent_app_country] => US [patent_app_date] => 2016-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 66 [patent_no_of_words] => 52606 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15270193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15975497 [patent_doc_number] => 10668049 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-02 [patent_title] => Methods of treating cognitive decline with transforming growth factor beta inhibitors [patent_app_type] => utility [patent_app_number] => 15/258862 [patent_app_country] => US [patent_app_date] => 2016-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 65 [patent_no_of_words] => 26336 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15258862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618344 [patent_doc_number] => 20170128531 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'TREATING NEURODEGENERATIVE DISEASES WITH PROGRANULIN' [patent_app_type] => utility [patent_app_number] => 15/255948 [patent_app_country] => US [patent_app_date] => 2016-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 20059 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15255948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11730575 [patent_doc_number] => 20170192017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'Methods For Detecting Phosphorylated Alpha-Synuclein' [patent_app_type] => utility [patent_app_number] => 15/247598 [patent_app_country] => US [patent_app_date] => 2016-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10879 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15247598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717209 [patent_doc_number] => 20170369559 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2017-12-28 [patent_title] => METHODS OF TREATING ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 15/239225 [patent_app_country] => US [patent_app_date] => 2016-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15239225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717209 [patent_doc_number] => 20170369559 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2017-12-28 [patent_title] => METHODS OF TREATING ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 15/239225 [patent_app_country] => US [patent_app_date] => 2016-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15239225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11444477 [patent_doc_number] => 20170045499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'NOCICEPTOR-LIKE CELLS DIFFERENTIATED FROM HUMAN NEURAL PROGENITORS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/235867 [patent_app_country] => US [patent_app_date] => 2016-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 10918 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15235867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16786115 [patent_doc_number] => 10988528 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-27 [patent_title] => Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy [patent_app_type] => utility [patent_app_number] => 15/750975 [patent_app_country] => US [patent_app_date] => 2016-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 24 [patent_no_of_words] => 27975 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12387789 [patent_doc_number] => 09963502 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-08 [patent_title] => Antibody that specifically binds partially processed or unprocessed neurotoxin polypeptides [patent_app_type] => utility [patent_app_number] => 15/230928 [patent_app_country] => US [patent_app_date] => 2016-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11253 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15230928 [rel_patent_id] =>[rel_patent_doc_number] =>)